Silverback raises $78.5M series B to send innate immunity activating therapies to clinic

As Silverback prepares to enter the clinic this year with its lead antibody-based cancer therapy, the biotech raised $78.5 million in a series B. U.S. Venture Partners, which led the round, was drawn to the potential of the therapy to stimulate the innate immune system through systemic delivery.

New investors Nextech

Read the full 512 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE